Australia's most trusted
source of pharma news
Tuesday, 26 November 2024
Posted 25 November 2024 AM
Moderna is on Pfizer's heels with its own updated mRNA Covid vaccine designed to target the Omicron sub-variant JN.1 approved by the TGA last week.
However, unlike Pfizer's Comirnaty JN.1 approved last month for Australians as young as six months, the TGA has approved Moderna's Spikevax JN.1 for individuals 12 years and older.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.